At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Parallel Study to Assess Tobacco-related Biomarkers of Exposure, Biomarkers of Potential Harm, and Nicotine Uptake During a 56-day Switch to Myblu E-cigarettes in Adult Smokers
In Brief
A clinical study evaluating Continue-smoking, myblu Tobacco 2.5%, and 4 other interventions for Healthy Volunteers. Completed, enrolled 240 participants across 1 site.
Detailed Summary
The purpose of this study is to assess changes in exposure to selected harmful and potentially harmful substances related to tobacco/nicotine use when adult smokers switch from their usual brand of combustible cigarettes to the myblu e-cigarette, for up to 56 days. This study is designed as an open-label, partially-randomized, parallel-arm, multi-site study in healthy adult smokers. Some subjects will be selected to take part in additional procedures as part of a pharmacokinetics (PK) sub-study.
Study Details
Timeline
Interventions
Ad-libitum use of subjects' usual brand combustible cigarette
Ad-libitum use of myblu e-cigarette with Tobacco flavor 2.5% nicotine
Ad-libitum use of myblu e-cigarette with Tobacco flavor 4.0% nicotine
Ad-libitum use of myblu e-cigarette with Honeymoon flavor 2.5% nicotine
Ad-libitum use of myblu e-cigarette with Honeymoon flavor 4.0% nicotine
Ad-libitum use of JUUL 5% e-cigarette